Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).

Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred.

Detalles Bibliográficos
Autores principales: Schlumberger, M., Abdelmoumene, N., Delisle, M. J., Couette, J. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033569/
https://www.ncbi.nlm.nih.gov/pubmed/7530987
_version_ 1782136866262220800
author Schlumberger, M.
Abdelmoumene, N.
Delisle, M. J.
Couette, J. E.
author_facet Schlumberger, M.
Abdelmoumene, N.
Delisle, M. J.
Couette, J. E.
author_sort Schlumberger, M.
collection PubMed
description Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred.
format Text
id pubmed-2033569
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20335692009-09-10 Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Schlumberger, M. Abdelmoumene, N. Delisle, M. J. Couette, J. E. Br J Cancer Research Article Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred. Nature Publishing Group 1995-02 /pmc/articles/PMC2033569/ /pubmed/7530987 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Schlumberger, M.
Abdelmoumene, N.
Delisle, M. J.
Couette, J. E.
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title_full Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title_fullStr Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title_full_unstemmed Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title_short Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
title_sort treatment of advanced medullary thyroid cancer with an alternating combination of 5 fu-streptozocin and 5 fu-dacarbazine. the groupe d'etude des tumeurs a calcitonine (getc).
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033569/
https://www.ncbi.nlm.nih.gov/pubmed/7530987
work_keys_str_mv AT schlumbergerm treatmentofadvancedmedullarythyroidcancerwithanalternatingcombinationof5fustreptozocinand5fudacarbazinethegroupedetudedestumeursacalcitoninegetc
AT abdelmoumenen treatmentofadvancedmedullarythyroidcancerwithanalternatingcombinationof5fustreptozocinand5fudacarbazinethegroupedetudedestumeursacalcitoninegetc
AT delislemj treatmentofadvancedmedullarythyroidcancerwithanalternatingcombinationof5fustreptozocinand5fudacarbazinethegroupedetudedestumeursacalcitoninegetc
AT couetteje treatmentofadvancedmedullarythyroidcancerwithanalternatingcombinationof5fustreptozocinand5fudacarbazinethegroupedetudedestumeursacalcitoninegetc

Ejemplares similares